Welcome to the e-CCO Library!

P517: Features of cytomegalovirus infection in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Makarchuk P., Belousova E., Volchkova E., Kudriavtseva E.

Created: Wednesday, 20 February 2019, 10:36 AM
P517: One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.
Year: 2021
Source: ECCO'21 Virtual
Authors: Chiappetta, M.F.(1);Viola, A.(1);Mastronardi, M.(2);Turchini, L.(3);Carparellli , S.(4);Orlando, A.(5);Biscaglia , G.(4);Miranda , A.(6);Guida, L.(7);Costantino, G.(1);Scaldaferri, F.(8);Bossa, F.(4);Renna, S.(5);Cappello , M.(7);Orlando , A.(5);Armuzzi, A.(3);Fries, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
Year: 2022
Source: ECCO'22
Authors: Vermeire, S.(1);Feagan, B.(2,3);Peyrin-Biroulet, L.(4);Oortwijn, A.(5);Faes, M.(6);de Haas, A.(5);Rogler, G.(7);
Created: Friday, 11 February 2022, 3:56 PM
P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-K. Park1*, C.S. Eun2, G.S. Seo3, J. Lim4, T.O. Kim5, D.I. Park1

Created: Thursday, 21 February 2019, 9:14 AM
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ramos Lopez, L.(1);Ramos-Díaz, R.(2);Alonso-Abreu, I.(1);Mourani-Padron, I.(2);Carrillo-Palau, M.(1);Reygosa, M.C.(1)*;Medina-Chico, S.(1);Gutierrez-Nicolas, F.(3);Nazco-Casariego, G.J.(3);Hernandez-Guerra, M.(4);
Created: Friday, 14 July 2023, 11:05 AM
P518 Ulcerative colitis drug development success rates are higher than the industry average
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Georgiev1, F. Hussain1, M. Copeman2, M. Delegge1, M.B. Gallagher1, T. Stewart1, W. Reinisch3

Created: Thursday, 30 January 2020, 10:12 AM
P518: Cardiovascular Risk Factors in Adolescents with inflammatory bowel disease: A Cross-sectional Population-Based Study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Ghersin*1, L. H. Katz2,3, S. Daher4, R. Shamir3,5, A. Assa3,5

Created: Friday, 22 February 2019, 9:41 AM
P518: Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.
Year: 2021
Source: ECCO'21 Virtual
Authors: Edwards, D.(1);Ibrahim, M.(2);Cooney, R.(2);Boulton, R.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic review
Year: 2022
Source: ECCO'22
Authors: Jatkowska, A.(1);White, B.(1);Gkikas, K.(1);Seenan, J.P.(2);MacDonald, J.(2);Gerasimidis, K.(1);
Created: Friday, 11 February 2022, 3:56 PM
P518: Remission induction in corticosteroid naïve children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tanaka T.*1, Goishi H.1, Kajihara T.1, Akagi M.1, Saniabadi A.2, Miura T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Lichtenstein, G.(2);Nakase, H.(3);Armuzzi, A.(4);Kucharzik, T.(5);Levy, G.(6);Palac, H.(6);Kujawski, M.(6);Klaff, J.(6);Cheon, J.H.(7);
Created: Friday, 14 July 2023, 11:05 AM
P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.-Y. Chao1,2*, S. Restellini1,3, C. Lemieux1, P. Germain1, A. Bitton1, P.L. Lakatos1,4, G. Wild1, E. Seidman1, T. Bessissow1, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. LEE1, L. Gilbert2, A. Srinivasan3, A. Lee4, D. van Langenberg3, C. Martin5, N. Ding1, M. Sparrow2

Created: Thursday, 30 January 2020, 10:12 AM
P519: Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Casanova, M.J.(1);Chaparro, M.(1);Nantes, Ó.(2);Varela, P.(3);Vela-González, M.(4);Montserrat, R.(5);Sierra, O.G.(6);Riestra, S.(7);Barreiro-de Acosta, M.(8);Martín-Rodríguez, M.M.(9);Gargallo-Puyuelo, C.J.(10);Reygosa, C.(11);Muñoz, R.(12);García de la Filia-Molina, I.(13);Núñez-Ortiz, A.(14);Kolle, L.(15);Calafat, M.(16);Huguet, J.M.(17);Iglesias-Flores, E.(18);Martínez-Pérez, T.J.(19);Bosch, O.(20);Duque-Alcorta, J.M.(21);Frago-Larramona, S.(22);Sánchez-Azofra, M.(23);Van Domselaar, M.(24);González-Cosano, V.M.(25);Bujanda, L.(26);Rubio, S.(2);Mancebo, A.(3);Castro, B.(5);García-López, S.(6);de Francisco, R.(7);Nieto, L.(8);Laredo, V.(10);Gutiérrez, A.(12);Mesonero, F.(13);Leo-Carnerero, E.(14);Cañete, F.(16);Ruiz, L.(17);Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P519: Anti-tumour necrosis-alpha therapy during pregnancy in patients with inflammatory bowel disease: safety in women and children
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bernardes C., Loureiro R., Carvalho D., Borges V., Russo P., Saiote J., Ramos J.

Created: Wednesday, 20 February 2019, 10:36 AM
P519: Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data
Year: 2021
Source: ECCO'21 Virtual
Authors: Hartl, C.(1);Novacek, G.(2);Reinisch, S.(2);Saciri, A.(1);Reinisch, W.(2);Primas, C.(2);Maier, H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P519: Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Friedrich, S.(1);Chua, L.(1);Zhang , X.C.(1);Clemow, S.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P519: Post-surgical recurrence predictors in the years 2000. Results of a retrospective single-centre long-term follow-up series and impact of imaging findings on outcomes
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Mendolaro*1, M. Daperno1, C. Randazzo2, A. Lavagna1, M. Mineccia3, M. Cosimato1, F. Bertolino4, C. Rigazio1, E. Ercole1, A. Ferrero3, R. Rocca1

Created: Friday, 22 February 2019, 9:41 AM
P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, J.M. Vázquez Morón2, H. Pallarés Manrique2, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, R. Perea Amarillo1, V. Merino3, A. Caunedo Álvarez1, F. Argüelles-Arias1

Created: Thursday, 21 February 2019, 9:14 AM
P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Nicolás de Prado1, C. Iniesta Navalón2, R. Gomez Espin1, M. Gil Candel2, L. Serrano Díaz1, L. Rentero Redondo2, J.J. Martinez Crespo1

Created: Thursday, 30 January 2020, 10:12 AM